金吾财讯 | 百奥赛图(02315)公布，公司近期已完成人工智能（“AI”）驱动抗体药物研发平台深度求索（以下简称“ DeepSeek”）的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。此次技术整合标志着抗体药物早期研发领域迈向智能化和数据化的新阶段，未来将为全球药企提供更精准及更具突破性的抗体药物研发方案，大大加速药物研发进程。百奥赛图于2020年启动“千鼠万抗”计划，针对1,000+潜在的抗体药物靶点，分别在自主开发的RenMab、RenLite及RenNano等全人抗体小鼠平台上进行抗体研发。目前已获得针对1,000+药物靶点的50万+的全人抗体序列分子，涵盖单抗、双抗及纳米抗体等各种抗体分子形式，兼具高亲和力、低免疫原性及成药性优势，未来该全人抗体分子库将快速提升至千万级别。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.